

Imugene HER-Vaxx peptides demonstrate high level of activity in preclinical testing

- **High levels of HER-2-specific antibodies generated in preclinical testing at the Medical University of Vienna**
- **HER-Vaxx fusion peptide antigens strongly immunogenic**
- **Antibodies recognize native HER-2 receptor**

Melbourne, 1 December 2014: Australian immuno-oncology company Imugene Limited (ASX:IMU) announces it has met another milestone in preclinical testing. The team at the Medical University of Vienna has shown that high HER-2-specific antibody levels have been generated using HER-Vaxx fusion peptide antigens, in preclinical testing, demonstrating that the HER-Vaxx fusion peptide antigens are strongly immunogenic.

HER-Vaxx is a peptide vaccine or immunotherapy. The peptide component in HER-Vaxx is the component that causes the immune system to generate cancer-fighting antibodies. As part of the ongoing preclinical work announced on 8th September 2014, the research of Professor Ursula Wiedermann has also found that the generated antibodies recognise native HER-2 protein, a result critical for eventual efficacy.

Professor Wiedermann, who is leading the research, is a member of the Imugene Scientific Advisory Board and was the principal investigator for the preclinical development of HER-Vaxx. She is also leading the design of the HER-Vaxx Phase Ib/II study for gastric cancer due to commence in 2015.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the \$US6.4 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer.

Charles Walker, CEO, said "These pleasing results form part of our preclinical testing needed to submit an IND and begin clinical testing with HER-Vaxx in patients with gastric cancer. It is gratifying to see strong results continuing to be generated, particularly with our more potent fusion peptides. We look forward to reporting continued progress in line with our plan to develop HER-Vaxx."

Charles Walker CEO

Tel: +61 (0) 4 5044 6990
Cwalker[at]imugene.com
www.imugene.com

Paul Hopper Executive Chairman

Tel: +1 858 334 5820 (US)
Tel: +61 406 671 515 (Australia)
receptogen[at]earthlink.net

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.